1. Generics Bulletin
  2. >>Legal & IP

US Court Says J&J Must Face Majority Of Purchasers’ Remicade Antitrust Suit

 
• By Dean Rudge

Purchasers of the Remicade infliximab brand in the US have accused Johnson & Johnson of an antitrust scheme effectively precluding infliximab biosimilars from competing. A US court says the originator must defend itself against the allegations, adding weight to Pfizer’s cause.

Traffic
US court allows majority of purchaser infliximab suit to proceed • Source: Shutterstock

Purchasers of Johnson & Johnson’s (J&J’s) Remicade (infliximab) accusing the originator of an anticompetitive scheme foreclosing biosimilar competition, namely Pfizer’s Inflectra (infliximab-dyyb) and Merck’s Renflexis (infliximab-abda), will have their day in court, after a US district court denied most of the originator’s motion to have the complaint dismissed.

In the consolidated suit, direct and indirect purchasers of the branded autoimmune diseases treatment alleged “artificially inflated prices and monopolization of the pharmaceutical market for biologic infliximab drugs,” achieved by J&J through “exclusive agreements and coercive bundled rebates

More from Legal & IP

After Jazz, Hikma Agrees $50m Settlement For ‘Most’ Xyrem ‘Pay-For-Delay’ Claims

 
• By Dean Rudge

Hikma said it would admit no wrongdoing or liability after reaching a preliminary settlement agreement over illicit ‘pay-for-delay’ claims involving its US version of Xyrem “that protects the company’s interests and provides clarity to our stakeholders.”

Viatris Pens Aprepitant Settlement Agreement After Kabi Loses Initial Patent Case

 
• By Dean Rudge

Viatris will look to introduce generic versions of Heron Therapeutics’ aprepitant brands, Cinvanti and Aponvie, around three years before patent expiry after settling litigation with the originator. Other court cases remain ongoing.

J&J Denied Injunction Over Private-Label Ustekinumab In US

 
• By Dave Wallace

Stelara originator J&J has been denied in its initial attempt to prevent Samsung Bioepis and ustekinumab biosimilar partner Sandoz from selling a private-label version of the product through a PBM in the US.

UK Forxiga SPCs Wiped Out As Trio Succeed With Plausibility Attack

 
• By Dean Rudge

Generic competition to AstraZeneca’s blockbuster SGLT2 inhibitor Forxiga (dapagliflozin) treatment for diabetes may hit England and Wales earlier than 2028 after a pair of SPCs were invalidated following proceedings initiated by a trio of generics manufacturers.

More from Generics Bulletin

Generics Bulletin Explains: The Landscape For Denosumab Biosimilar Competition

 
• By Dave Wallace

One of the biggest biologic loss-of-exclusivity opportunities of the year is almost upon us, as biosimilars developers across the world get ready to launch rivals to Amgen’s denosumab brands Prolia and Xgeva. Generics Bulletin offers a rundown of some of the major contenders and how they view the market.

Trump Order On Domestic Manufacturing Wins Plaudits From Industry

 
• By Dave Wallace

An executive order from US president Donald Trump aimed at incentivizing domestic manufacturing of critical medicines has been welcomed by the US Association for Accessible Medicines.

Teva And Alvotech Celebrate Interchangeability For US Ustekinumab

 
• By Dave Wallace

The market for biosimilar rivals to Stelara continues to be hotly contested in the US, with partners Teva and Alvotech claiming a boost from an interchangeability designation at the same time as Biocon Biologics highlighted fresh market access agreements.